Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Serbia Extends Galenika Tender to Mid-June for Valeant Unit

Don't Miss Out —
Follow us on:

May 30 (Bloomberg) -- Serbia extended its tender for the Galenika AD drug company for a fourth time, giving a unit of Canada’s Valeant Pharmaceuticals International Inc. until June 14 to file a bid, the Finance Ministry said on its website.

The government first called for bidders on Jan. 15, seeking a partner among drugmakers with operating revenue of at least 200 million euros ($$259.5 million) in 2011.

Galenika cut its 2012 loss to 5.6 billion dinars ($65.2 million) from 13.5 billion dinars a year earlier.

To contact the reporter on this story: Gordana Filipovic in Belgrade at gfilipovic@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.